The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s enzyme inhibitor market report forecasts the enzyme inhibitor market size to grow to $196.29 Billion by 2027, with a CAGR (compound annual growth rate) of more than 2%.

Learn More On The Enzyme Inhibitor Market Report 2023 – https://www.thebusinessresearchcompany.com/report/enzyme-inhibitor-global-market-report

Enzyme Inhibitor Market Size Forecast
The global enzyme inhibitor market is expected to grow from $173.2 billion in 2022 to $177.82 billion in 2023 at a compound annual growth rate (CAGR) of 2.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The enzyme inhibitor market size is expected to grow to $196.29 billion in 2027 at a CAGR of 2.5%.

North America held the largest enzyme inhibitor market share, and Asia-Pacific was the fastest-growing region in 2022.

Key Enzyme Inhibitor Market Driver ­– Rise In The Incidence Of Diseases Including Cancer
For instance, according to the World Health Organization, 19.3 million new cancer cases were registered, and almost 10.0 million cancer deaths occurred in 2020. In addition, there were more than 1.6 million people diagnosed with cancer in the US. Therefore, the rise in the incidence of diseases like cancer is driving the demand for the enzyme inhibitor market.

Request for A Sample Of The Global Enzyme Inhibitor Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=6728&type=smp

Key Enzyme Inhibitor Market Trend – Strategic Partnerships And Collaborations
Major companies operating in enzyme inhibitors are focused on strategic partnerships to meet customer demand. For instance, in April 2021, Artios Pharma Limited, a UK-based DNA damage response company that also provides enzyme inhibitors, collaborated with Novartis International AG, a Switzerland-based pharmaceutical corporation, to uncover and verify new generation DDR (DNA Damage Response) targets to advance Novartis’ Radioligand Therapies (RLT). This partnership with Novartis will be utilized to find and validate next-generation DDR targets to improve Novartis’ radioligand therapies. Furthermore, in March 2020, Bayer AG, a Germany-based pharmaceutical and life sciences company, collaborated with Curadev, an Indian-based pharmaceutical company that provides enzyme inhibitors, to discover new drug candidates to provide treatment for lung diseases, cardiovascular diseases, and other inflammatory diseases.

Enzyme Inhibitor Market Segment
1) By Type: Proton Pump Inhibitors (PPIs), Protease Inhibitors, Reverse Transcriptase Inhibitors, Aromatase Inhibitors, Kinase Inhibitors, Neuraminidase Inhibitors, Statins, Other Types
2) By Disease Indication: Chronic Obstructive Pulmonary Disorders, Cardiovascular Disease, Gastrointestinal Disorders, Arthritis, Inflammatory Diseases, Other Disease Indications
3) By Application: Chemotherapy, Antibiotics, Pesticides, Cardiovascular Treatments, Other Applications
4) By End User: Pharmaceutical, Biotechnology, Food and Beverage, Other End Users

Enzyme Inhibitor Market Major Players and Strategies
Major players in the enzyme inhibitor market are Abbott Laboratories, Amgen Inc., AstraZeneca PLC, Bayer AG, F. Hoffmann-La Roche AG, Pfizer Inc., Ranbaxy Laboratories, Takeda Pharmaceutical Company, Merck and Co. Inc., Eli Lilly and Company, Bristol Myers Squibb, Cipla USA Inc., AbbVie, Teva Pharmaceutical Industries Ltd., and Janssen Pharmaceuticals.

In March 2021, Amgen Inc., a US-based biotechnology company, acquired Rodeo Therapeutics Corporation for a deal amount of $666 million. Through this acquisition, Rodeo is focused on developing first-in-class, orally available modulators of prostaglandin biology that play an important role in tissue regeneration and repair. Rodeo Therapeutics Corporation is a US-based biopharmaceutical company that develops enzyme inhibitors.

The Enzyme Inhibitor Global Market Report 2023 covers regional data on enzyme inhibitor market size, enzyme inhibitor market trends and drivers, opportunities, strategies, and enzyme inhibitor market competitor analysis. The countries covered in the enzyme inhibitor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Enzyme inhibitor refers to a chemical that inhibits an enzyme’s activity. Enzymes participate in a variety of cell processes, including cell signalling, growth, and division, as well as accelerating chemical reactions in the body. Enzymes help to speed up chemical reactions in the body and take part in many cell functions, including cell signaling, growth, and division.

View More Reports Related To The Enzyme Inhibitor Market –
Specialty Enzymes Global Market Report 2023
Diagnostic Enzyme Global Market Report 2023
Enzymes Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: